Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant  or a left ventricular assist device (LVAD).

UH Cleveland Medical Center. Image courtesy of University Hospitals
News | Deep Vein Thrombosis (DVT)
Four Prospective, Multicenter Studies Support Use of Drug-Coated Balloons Over Bare Metal Stents in Treating Femoropopliteal Lesions

November 21, 2022 —  New research published in the Journal of the American College of Cardiology shows the use of drug ...

Home November 21, 2022
Home
Cardiovascular disease remains the leading cause of death in the United States (US) and worldwide, according to the American Heart Association.
News | Heart Failure
Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology

November 21, 2022 — Cardiovascular disease remains the leading cause of death in the United States (US) and worldwide ...

Home November 21, 2022
Home
Justin Balko, PharmD, PhD, Ingram Associate Professor of Cancer Research, and a co-corresponding author of the study. Credit: Vanderbilt University Medical Center
News | Heart Failure
Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis

November 22, 2022 — Myocarditis is a complication that can occur in cancer patients treated with immune checkpoint ...

Home November 21, 2022
Home
Certain adults with this artery-blocking condition may see more benefits with an open bypass compared to less-invasive procedures to improve circulation.
News | Peripheral Artery Disease (PAD)
Bypass Surgery Favorable for Initial Treatment of Chronic Limb-Threatening Ischemia

November 15, 2022 Performing open bypass surgery to restore circulation for people with a severe form of peripheral ...

Home November 15, 2022
Home
UMSOM researchers display first genetically modified pig heart transplanted into living patient. Image courtesy of University of Maryland School of Medicine
News | Heart Failure
Unexpected Electrical Changes Seen in First Successful Transplant of Genetically-Modified Pig Heart

November 15, 2022 — Ten months after transplanting the first genetically-modified pig heart into a human patient ...

Home November 15, 2022
Home
When it comes to heart failure (HF), sex differences are known to impact everything from risk factors to clinical presentation to response to treatment, making sex a key factor to consider in studies of emerging pharmacotherapies.
News | Heart Failure
Study Shows Heart Failure Treatment With Dapagliflozin Consistently Benefited Both Men and Women

November 14, 2022 — When it comes to heart failure (HF), sex differencesare known to impact everything from risk factors ...

Home November 14, 2022
Home
Reduction in the risk of death or major bleeding after primary PCI in patients with STEMI treated with heparin monotherapy (blue curve) or bivalirudin with a post-procedure infusion (red curve). The hazard ratio of 0.69 signifies a 31% reduction in risk. The ARR (absolute risk reduction) was 1.3%. The NNT (number of patients needed to treat to prevent one death or large bleed) was 76. Image courtesy of Mount Sinai Health System
News | Antiplatelet and Anticoagulation Therapies
Bivalirudin Found to be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

Home November 14, 2022
Home
The "Trending Topics at Sessions 2022" panel of experts featured Manesh R. Patel, MD, FACC, FAHA, Chair of the Committee on AHA 2022 Scientific Sessions, to review highlights and lessons learned from the event.
News | AHA
AHA 2022 Trending Topics: Clinical Trials, Scientific Studies and AI

November 14, 2022 — The American Hospital Association Scientific Sessions 2022, held Nov. 5-7 in Chicago, IL, presented ...

Home November 14, 2022
Home
Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge
News | Heart Failure
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

November 9, 2022 —  Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 ...

Home November 09, 2022
Home
Robert J. Mentz, M.D., Associate Professor of Medicine, Chief, Heart Failure Section, Associate Program Director, Duke Cardiology Fellowship, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, image copyright Robert J. Mentz
News | AHA
TRANSFORM-HF Trial Found No Difference in Effectiveness Between 2 Common Loop Diuretics

November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication ...

Home November 08, 2022
Home
Julian D. Gillmore, M.D., Ph.D., Professor, University College London Centre for Amyloidosis, United Kingdom, image copyright University College London Centre for Amyloidosis
News | AHA
Novel Gene-Editing Therapy Shows Promise For Patients With Transthyretin Amyloid Cardiomyopathy

November 8, 2022 — A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly ...

Home November 08, 2022
Home
New guidance covers recommendations for surgery, imaging, family screening, and the importance of a multidisciplinary team
News | ACC
AHA and ACC Issue New Guideline on Aortic Disease

Nov. 4, 2022 — The American College of Cardiology and the American Heart Association have published a new guideline on ...

Home November 05, 2022
Home
Fig. 1. Selective reduction of succinyl-CoA among the TCA cycle metabolites in cardiac muscle during chronic HF. Relative levels of the TCA cycle metabolites in cardiac muscles isolated from myocardial infarction (MI) mice, compared with those from sham mice, 28 d after surgery. Each data point in the dot plot represents one individual mouse sample (n = 38 for both groups for all metabolites, except for succinyl-CoA in which n = 18 for both groups). Concentrations of succinyl-CoA in these samples were 2.2–5
News | Heart Failure
How Heart Failure Disrupts the Cell's Powerhouse

November 3, 2022 — Chronic heart failure causes the cell’s powerhouses to dysfunction, in part due to overconsumption of ...

Home November 03, 2022
Home
About one-fifth of implants of left ventricular-assist devices have the complication of right heart failure. Abbott Laboratories (adapted)
News | Ventricular Assist Devices (VAD)
Study Sifts Potential Factors of Device-Implant Complication

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

Home November 02, 2022
Home
Impella RP Flex with SmartAssist Illustration (Photo: Business Wire)
News | Hemodynamic Support Devices
Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

November 1, 2022 —  Abiomed announced that Impella RP Flex with SmartAssist has received U.S. Food and Drug ...

Home November 01, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now